Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 5/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.31 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25133512 | 0.93 | CHRM5 (0.42) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 | |
| SCHEMBL25133300 | 0.89 | SLC6A1 (0.34) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 | |
| SCHEMBL25133303 | 0.89 | SLC6A1 (0.34) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 | |
| SCHEMBL25133298 | 0.89 | SLC6A1 (0.34) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 | |
| SCHEMBL21472825 | 0.87 | ACHE (0.39) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 | |
| SCHEMBL16282944 | 0.86 | CHRM5 (0.43) | CHRM5ADRA2CACHE | |
| SCHEMBL14422030 | 0.84 | GBA1 (0.48) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 | |
| SCHEMBL23919059 | 0.84 | GNAO1 (0.44) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 | |
| SCHEMBL23765778 | 0.82 | GNAO1 (0.36) | GNAO1GNAI3GNAI1 | |
| Hydrochloric Acid SCHEMBL5573130 | 0.82 | GBA1 (0.47) | CACNA2D1CACNA1BCACNB1GBA1GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315896-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CACNA2D1 3469/4885CACNA1B 3234/4885CACNB1 2077/4885 |
| US-20230097358-A1 | INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE | LRRK2, CRBN, MDM2 | CACNA2D1 3469/4885CACNA1B 3234/4885CACNB1 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.